Axial spondyloarthritis (axSpA) is a chronic inflammatory disorder affecting the spine and sacroiliac joints, causing persistent back pain, stiffness, and reduced mobility. It includes ankylosing spondylitis (radiographic axSpA) and non-radiographic axSpA, the latter showing no structural damage on X-rays. Symptoms often appear in early adulthood, with significant underdiagnosis due to subtle initial signs.

The disease management involves NSAIDs, biologics, monoclonal antibodies, and physical therapy, targeting inflammation and slowing disease progression. In June 2020, Taltz® (ixekizumab) became the first IL-17A antagonist approved by the FDA for non-radiographic axSpA, highlighting the rise of targeted immunotherapies.

Axial Spondyloarthritis (axSpA) Pipeline Analysis

The Axial Spondyloarthritis Pipeline Analysis Report by Expert Market Research provides a comprehensive review of therapeutics under clinical development, including over 100 pipeline drugs from 50+ companies. The report evaluates drug class, clinical phase, safety, efficacy, and route of administration, offering a detailed view of market trends and innovation.

Pipeline Segmentation by Phase

Phase II & III: 31%, representing the largest share of active trials

Phase IV: 28%, post-marketing studies ensuring long-term safety

Phase I & Early Phase: remaining share, indicating ongoing early-stage research

Pipeline Segmentation by Drug Class

Small molecules – oral anti-inflammatory and immunomodulatory agents

Monoclonal antibodies – targeted therapies against cytokines like IL-17

Biologics – advanced immune-modulating therapies

RNA-based therapeutics – precision gene-targeted approaches

Peptides – emerging treatment options with selective mechanisms

Route of Administration

Oral – convenient, systemic therapies

Parenteral – injectable biologics and monoclonal antibodies

Others – novel delivery platforms under investigation

Key Pipeline Highlights

Secukinumab (IL-17A inhibitor): Evaluated in the AScalate trial as a first-line biologic to improve disease control and support treat-to-target strategies

RNA-based therapies: Emerging as precision treatments to modulate inflammatory pathways and halt disease progression

Combination strategies: Integrating biologics with standard-of-care approaches to enhance efficacy

Axial Spondyloarthritis (axSpA) Epidemiology

Prevalence: 0.9–1.4% in the U.S., 0.66–1.3% in the U.K.

Diagnostic prevalence: 0.2–0.7%, reflecting significant underdiagnosis

Projected arthritis burden: 78 million U.S. adults by 2040, driving demand for effective axSpA therapies

Request a free sample report and explore the full table of contents today.

Key Players in Clinical Trials

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Sinocelltech Ltd., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Biocad, XBiotech, Inc., Care Arthritis Ltd.

Pfizer, Novartis Pharmaceuticals, GlaxoSmithKline, UCB Biopharma SRL

These companies are advancing novel biologics, monoclonal antibodies, RNA-based therapeutics, and small molecules to meet unmet treatment needs in axSpA management.